Showing 1561-1570 of 1735 results for "".
- Vabysmo Showed Extended Durability, Continued Efficacy and a Consistent Safety Profile in Long-Term DME Studyhttps://modernod.com/news/vabysmo-showed-extended-durability-continued-efficacy-and-a-consistent-safety-profile-in-long-term-dme-study/2482363/At the American Society of Retina Specialists (ASRS) 2024 Annual Meeting in Stockholm, Sweden, Genentech announced new, 4-year data from the RHONE-X extension study. The study met all primary endpoints, showing that Vabysmo (faricimab-svoa) was well tolerated in people with diabetic mac
- Aurion Biotech Completes Enrollment In Phase 1/2 Clinical Trial of Allogeneic Cell Therapy Candidatehttps://modernod.com/news/aurion-biotech-completes-enrollment-in-phase-12-clinical-trial-of-allogeneic-cell-therapy-candidate/2482306/Aurion Biotech announced that it has completed dosing of all subjects in its phase 1/2 clinical trial (CLARA) of AURN001, an allogeneic cell therapy for the treatment of corneal edema secondary to corneal endothelial dysfunction. “Aurion Biotech is delighted that both enrollm
- Aurion Biotech Announces Completion of Enrollment in Phase 1/2 Clinical Trialhttps://modernod.com/news/aurion-biotech-announces-completion-of-enrollment-in-phase-12-clinical-trial/2482253/Aurion Biotech announced it has completed dosing of all subjects in its phase 1/2 clinical trial (CLARA) of AURN001, an allogeneic cell therapy for the treatment of corneal edema secondary to corneal endothelial dysfunction. AURN001 is a combination cell therapy product (biologic/d
- Zeiss Completes Acquisition of Dutch Ophthalmic Research Center (DORC)https://modernod.com/news/carl-zeiss-meditec-completes-acquisition-of-dutch-ophthalmic-research-center/2482210/Carl Zeiss Meditec announced it has secured all required regulatory approvals and completed the acquisition of Dutch Ophthalmic Research Center (DORC). IN December, Zeiss announced its plans to acquire from the investment firm Eurazeo SE (Paris, France) for about €985 million ($1.0
- Opthea Completes Enrollment in First Pivotal Trial of Sozinibercept for Wet AMDhttps://modernod.com/news/opthea-completes-enrollment-in-first-pivotal-trial-with-sozinibercept/2482114/Opthea announced it has completed enrollment of all patients in the COAST phase 3 pivotal clinical trial investigating sozinibercept (OPT-302, a vascular endothelial growth factor (VEGF)-C/D inhibitor) in combination with aflibercept, an anti-VEGF-A therapy, for the treatment of wet age-rela
- iuvo BioScience Acquires Promedica International to Expand Ophthalmic Clinical CRO Serviceshttps://modernod.com/news/iuvo-bioscience-acquires-promedica-international-to-expand-ophthalmic-clinical-cro-services/2482070/Partner Research Organization iuvo BioScience announced it has acquired Promedica International (PMI), an ophthalmology-focused clinical CRO. Financial terms of the deal were not disclosed. The companies say the combined organization will support all aspects of opht
- Iridex Confirms Medicare Administrative Contractors Retired Local Coverage Determinations that Restricted Cyclophotocoagulationhttps://modernod.com/news/iridex-confirms-medicare-administrative-contractors-retired-local-coverage-determinations-that-restricted-cyclophotocoagulation/2482036/Iridex announced all five Medicare Administrative Contractors (MACs) retired their local coverage determinations (LCDs) that were scheduled to take effect on January 29, 2024. Iridex and other stakeholders opposing the LCDs have engaged with the MACs throughout the comment period to advocate
- LENZ Therapeutics and Graphite Bio Announce Mergerhttps://modernod.com/news/lenz-therapeutics-and-graphite-bio-announce-merger/2481971/LENZ Therapeutics and Graphite Bio announced that they have entered into a definitive merger agreement to combine the companies in an all-stock transaction. The lead programs of the combined company will address presbyopia. The combined company is expected to trade on Nasdaq under the t
- Oculis Appoints Rebecca Weil, PhD, as Chief Commercial Officer as it Enters Pre-Commercial Phasehttps://modernod.com/news/oculis-appoints-rebecca-weil-phd-as-chief-commercial-officer-as-it-enters-pre-commercial-phase/2481823/Oculis announced the appointment of Rebecca Weil, PhD, to the role of Chief Commercial Officer. In this role, Ms. Weil will lead the organization to commercial readiness from designing launch strategies for US and globally, and building the required commercial infrastructure to bring all of
- BVI Expands its Presence in Spain and Portugal Acquiring Medical Mixhttps://modernod.com/news/bvi-expands-its-presence-in-spain-and-portugal-acquiring-medical-mix/2481813/BVI announced it has acquired Medical Mix, an ophthalmic medical device supplier in Spain and Portugal. Financial terms of the deal were not disclosed. BVI said its European footprint with direct sales representatives and infrastructure now spans all major western Eu